ELDUXIO 76 mg Injection ELDUXIO contains Elranatamab, a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager antibody. It simultaneously binds to BCMA expressed on the surface of multiple myeloma cells and CD3 expressed on T-lymphocytes. This targeted binding redirects endogenous T-cells to attack and lyse BCMA-expressing myeloma cells, inducing targeted cytotoxic activity. It is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.